The 48-month OS rate for the TRANSFORM plus long-term follow-up study was 61.5% for patients with R/R LBCL.
Manali Kamdar, MD
Advertisement
Articles by Manali Kamdar, MD
Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC
2
Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma
3
Novel Treatment Displays Tolerability in Relapsed/Refractory B-Cell ALL
4
T-DM1 Confers Lower Cardiotoxicity Risk in HER2+ Advanced Breast Cancer
5
